Intracavernosal Platelet Rich Plasma with Phosphodiesterase Type 5 Inhibitors Versus Phosphodiesterase Type 5 Inhibitors in Management of Erectile Dysfunction: A comparative randomized study

Document Type : Original Article

Authors

Urology department , Faculty of Medicine, Aswan University

Abstract

Background: Erectile Dysfunction (ED) is defined as inability to achieve and/or maintain an erection sufficient for satisfactory sexual performance. Objective: To assess the use of intracavernosal injection of platelet rich plasma (PRP) with and without oral Phosphodiesterase type 5 inhibitors for treatment of ED. Methods: A prospective randomized study included 38 Patients. They were randomly allocated in two groups, 19 each. The two group was treated by daily Phosphodiesterase type 5 inhibitors (tadalafil 5 mg). Group A had intracavernosal injection of PRP, while group B had saline 0.9% (placebo). All patients answered the Arabic version of IIEF-5 questionnaire in structured interview before and 3 months after initiation of therapy. Results: The mean ILEF-5 score in group A was 9.84 before which increased to 17.6 after injection (p-value> 0.001), Meanwhile, the mean ILEF-5 score in group B before injection was 9.89 and after injection was 12.9 (p-value > 0.001). Furthermore, the mean difference for (ILEF-5) score between both groups after injection was 4.68 (p-value > 0.014). Conclusion: ICI of PRP with PDE5 inhibitors improves erectile function and patient satisfaction more than PDE5 inhibitors alone and might be an optional treatment for patients with erectile dysfunction.

Keywords

Main Subjects

Files

Share

How to cite

Statistics